Johnson & Johnson Reports Q1 2022 Results
Total sales growth of 5.0% to $23.4 Billion with operational growth of 7.7%* and adjusted operational growth of 7.9%* Earnings per share of $1.93 decreasing 16....
Source: prnewswire.com
Page 2 - Severe Plaque News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Severe Plaque. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Severe Plaque Today - Breaking & Trending Today
Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis
Share this article Share this article INDIANAPOLIS, April 23, 2021 /PRNewswire/ -- Through clinical trial meta-analysis and real-world evidence, Eli Lilly and Company's (NYSE: LLY) Taltz ® (ixekizumab) demonstrated greater success in key measured treatment outcomes compared to other biologics in adults with moderate to severe plaque psoriasis. In the first one-year network meta-analysis based on area under the curve, Taltz showed numerically greater cumulative benefits on completely clear skin over one year compared to seven other biologics, as measured by Psoriasis Area Severity Index (PAS...
Source: prnewswire.com
Unichem Labs spurts on USFDA nod for psoriasis drug
Unichem Laboratories surged 5.71% to Rs 323.05 after the company received United States Food and Drug Administration (USFDA) approval for apremilast tablets, 10 mg, 20 mg and 30 mg. The drug is a generic version of Amgen's Otezla (apremilast) tablets, 10 mg, 20 mg, and 30 mg. The drug is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. The scrip extended gains for third day. The stock has added 6.67% in three sessions from its recent closing low of Rs 302.85 recorded on 16 February 2021. In the pas...
Source: business-standard.com